PT  - JOURNAL ARTICLE
AU  - Heather D. Hirsch
AU  - Elim Shih
AU  - Holly L. Thacker
TI  - ERAAs for menopause treatment: Welcome the ‘designer estrogens’
AID  - 10.3949/ccjm.84a.15140
DP  - 2017 Jun 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 463--470
VI  - 84
IP  - 6
4099  - http://www.ccjm.org/content/84/6/463.short
4100  - http://www.ccjm.org/content/84/6/463.full
SO  - Cleve Clin J Med2017 Jun 01; 84
AB  - Estrogen receptor agonist-antagonists (ERAAs) selectively inhibit or stimulate estrogen-like action in targeted tissues. This review summarizes how ERAAs can be used in combination with an estrogen or alone to treat menopausal symptoms (vasomotor symptoms, genitourinary syndrome of menopause), breast cancer or the risk of breast cancer, osteopenia, osteoporosis, and other female midlife concerns.